Dr. Christopher Donnelly, PhD, is the first recruit for the University of Pittsburgh Brain Institute’s new Live Like Lou Center for ALS Research. A neurobiologist who co-led a study investigating hexanucleotide repeat expansion (HRE) which scientists say is the most common cause of Amyotrophic Lateral Sclerosis (ALS) and…
News
Johns Hopkins University researchers have announced that they will present the latest results of a study that reveals increased levels of endothelin 1 (ET-1) in astrocytes in the brain, along with increased levels of ET-B binding protein (the protein that binds to the ET-1 receptor) are associated with amyotrophic lateral sclerosis (ALS) or Lou…
The launch of Answer ALS, the largest comprehensive research project to cure Amyotrophic Lateral Sclerosis (ALS) was announced in a press release by the Johns Hopkins University’s Robert Packard Center for ALS Research in Baltimore, MD, the Cedars-Sinai…
MediciNova, a biopharmaceutical company that creates and studies small molecule medications for the management of medical conditions with unmet medical needs, is currently undergoing research on ALS patients who use non-invasive ventilation and will be treated with MN-166, also called Ibudilast, as part of a study on the management of ALS. Currently there…
In a recent paper entitled “Spinal Locomotor Circuits Develop Using Hierarchical Rules Based on Motorneuron Position and Identity” published in the Neuron journal, a team of researchers from the Salk Institute for Biological Sciences, La Jolla, CA and the University of Texas,…
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs for the treatment of cancer and other major diseases, recently announced the evaluation of its SINE nuclear transport compound KPT-350 as a treatment for Amyotrophic Lateral Sclerosis (ALS). Results from preclinical studies will…
Almost 6 million Americans are living with some form of paralysis, including nearly 1.3 million who have suffered spinal cord injuries. However, a team of University of California at Los Angeles (UCLA) scientists reports this week that a 39-year-old man who has been completely paralyzed for four years was…
A recent study indicates that a respiratory pacemaker intended to assist breathing in people with amyotrophic lateral sclerosis (ALS) may actually reduce survival in those with the neurodegenerative disorder. The study, titled “Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis…
In a recent study entitled “Complex Inflammation mRNA-Related Response in ALS is Region Dependent” characterizes the inflammatory response in patients with Amyotrophic lateral sclerosis (ALS)” published in the journal Neural Plasticity, a research team led by Isidre Ferrer from the L’Hospitalet de Llobregat in Spain detected…
Synapse Biomedical Inc., a company that commercializes the NeuRx Diaphragm Pacing System (DPS), has recently announced it will be presenting data on the company’s Post Approval Study (PAS), a multi-center trial that demonstrated DPS’s safety and survival benefit, during the 26th International Symposium on ALS/MND. Data will be presented by Dr. Robert Miller, Principal Investigator of the…